IL6 and kidney disorder: The selected miRNAs were validated as up‐regulated after RTX treatment included main regulators of inflammation, atherosclerosis, CV disease and nephropathy (ie miR‐28‐5p, miR‐106‐3p and miR‐148b‐3p),35, 36, 37, 38 as well as inhibitors of IL‐6 production (ie miR‐151a‐3p).39 Similar in the case of RA, the changes promoted by RTX therapy in that miRNAs were found parallel to the changes promoted in both disease activity and the inflammatory profile of these patients.